Gynaecomastia during antituberculosis chemotherapy with isoniazid.
Dixit
Ramakant
R
Sharma
Sidharth
S
Nawal
C L
CL
D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006177:Gynecomastia / Q000188:drug therapy*; D006801:Humans; D007194:India; D007538:Isoniazid / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D011718:Pyrazinamide / Q000008:administration & dosage / Q000009:adverse effects; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects; D014388:Tuberculosis, Lymph Node / Q000188:drug therapy*
D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin